Antihypertensive effect of roselle (Hibiscus sabdariffa) calyx infusion in spontaneously hypertensive rats and a comparison of its toxicity with that in Wistar rats

The LD50 of roselle calyx extract and its effect on blood pressure were determined. The LD50 was found to be above 5000 mg kg−1. Roselle calyx infusion was found to lower significantly (p<0·05) both systolic and diastolic pressure in spontaneously hypertensive and normotensive Wistar–Kyoto rats at tested doses of 500 and 1000 mg kg−1 body weight. The reduction in blood pressure in both groups was positively correlated with weight. Continuous consumption of the infusion at 1000 mg kg−1 was discovered to lead to sudden death in spontaneously hypertensive rats but not in Wistar‐Kyoto rats. Water intake was not significantly different (p>0·05) in the control groups of the two strains of rats used, neither was there a significant difference in their urine output. The water intake in the treated spontaneously hypertensive and normotensive rats was not different from the corresponding control groups. However the urine output of the treated spontaneously hypertensive rats was significantly higher. A significant decrease in serum creatinine, cholesterol, and glucose in the treated rats compared with the control as well as a significant increase in serum uric acid was observed. The serum proteins (albumin and total protein) in the treated rats when compared with the control groups was not changed significantly. Copyright © 1999 John Wiley & Sons, Ltd.

[1]  W. Watson,et al.  Albumin standards and the measurement of serum albumin with bromcresol green. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[2]  M. Muldoon,et al.  Flavonoids and heart disease , 1996, BMJ.

[3]  I. U. Haq,et al.  Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease , 1995, The Lancet.

[4]  J. Kjekshus,et al.  -Blockers and Sudden Cardiac Death , 1995, Annals of Internal Medicine.

[5]  N. Lam,et al.  Effect of Diuretic Drugs on Creatinine Clearance Determination , 1995, Therapeutic Drug Monitoring.

[6]  A. Heagerty,et al.  Hyperlipidaemia, hypertension, and coronary heart disease , 1995, The Lancet.

[7]  S. Rosansky,et al.  The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. , 1990, Archives of internal medicine.

[8]  P. Weidmann,et al.  Effects of posture and ageing on circulating atrial natriuretic peptide levels in man. , 1987, Journal of hypertension.

[9]  P. Poole‐Wilson.  Diuretics, hypokalaemia and arrhythmias in hypertensive patients: still an unresolved problem. , 1987, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[10]  J. Hindler,et al.  Aminoglycoside resistance: a worldwide perspective. , 1986, The American journal of medicine.

[11]  K. Anderson,et al.  A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the framingham study , 1986 .

[12]  J. Huttunen,et al.  Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. , 1985, JAMA.

[13]  P. Hill,et al.  Elevation of serum lipid levels during diuretic therapy of hypertension. , 1976, The American journal of medicine.

[14]  R. A. Norman,et al.  Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. , 1972, The American journal of medicine.

[15]  T. H. Steele.  Evidence for altered renal urate reabsorption during changes in volume of the extracellular fluid. , 1969, The Journal of laboratory and clinical medicine.

[16]  A. Breckenridge.  Hypertension and Hyperuricæmia , 1966, Proceedings of the Royal Society of Medicine.

[17]  W. T. Caraway.  Determination of uric acid in serum by a carbonate method. , 1955, American journal of clinical pathology.

[18]  A. Gornall,et al.  Determination of serum proteins by means of the biuret reaction. , 1949, The Journal of biological chemistry.

[19]  J. Brod,et al.  THE RENAL CLEARANCE OF ENDOGENOUS "CREATININE" IN MAN. , 1948, The Journal of clinical investigation.

[20]  L. Chambless,et al.  Frequency and clustering of nonlipid coronary risk factors in dyslipoproteinemia. The Lipid Research Clinics Program Prevalence Study. , 1986, Circulation.

[21]  J. Ockene.  Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1985, The American journal of cardiology.

[22]  C. Bulpitt,et al.  Influence of anti-hypertensive therapy on serum cholesterol in elderly hypertensive patients. Results of trial by the European Working Party on High blood pressure in the Elderly (EWPHE). , 1982, Acta cardiologica.

[23]  H. Lewerenz.  Evaluation of certain food additives. Twenty-first Report of the Joint FAO/WHO Expert-Commitee on Food Additives. Technical Report Series 617. 41 Seiten. World Health Organisation, Geneve 1978. Preis: 5,– sfrs. , 1979 .

[24]  J. Robertson,et al.  Arterial hypertension : the gestation and birth of a WHO Expert Committee report , 1979 .

[25]  A. Breckenridge.  Hypertension and hyperuricaemia. , 1966, Lancet.